# Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort)

Source: https://welltoldgrants.com/grants/rfa-ip-24-046-nationwide-cohort-to-estimate-burden-of-respiratory-viruses/  
Official notice: https://www.grants.gov/search-results-detail/350452

> Centers for Disease Control and Prevention - ERA offered grants of up to $4.5 million (at least $3.0 million) to nonprofits, colleges and universities, state and local governments, tribes and businesses. It expected to make one award worth $26.5 million in total. Applications closed on February 16, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-IP-24-046 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | February 16, 2024 |
| Award ceiling | $4.5 million |
| Award floor | $3.0 million |
| Expected awards | 1 |
| Total funding | $26.5 million |
| Cost sharing | not required |
| Assistance Listings | 93.083 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses

## What the grant funds

This project would establish and sustain a national longitudinal cohort of repeat blood donors with the purpose of monitoring changes in antibody titers against common or novel respiratory viruses; surveying the donors to assess for risk factors for infection, vaccination status, respiratory symptoms, and severe illness; and establishing a repository for further analysis as new assays to measure the immune response to respiratory virus infections are developed. During the COVID-19 pandemic, CDC used a contract mechanism to fund national serosurveillance studies, which used regular antibody assessments and surveys to monitor the burden of infection, risk factors for infection, and explore the duration and extend of immunity by population throughout the US (2020-2022). By 2022, algorithms for using quantitative antibody titers to detect reinfection were established and tested, creating novel systems for monitoring burden even in the setting of high overall seroprevalence. Adapting these tools to the current context, this research cooperative agreement would establish a large-scale longitudinal cohort (>50,000 persons) of repeat blood donors with the purpose of: 1) estimating the national burden of incident SARS-CoV-2 infection, and further adapting the approach to other respiratory viruses as technology allows including Respiratory Syncytial Virus, Influenza, Human Metapneumovirus, EVD-68, and others; 2) determining antibody thresholds for protection across multiple respiratory viruses; 3) assessing state- or region-specific population-level immunity to/risk for infection through tracking median antibody titers within various populations; and 4) monitoring waning immunity and changes in immune capabilities in the context of ongoing viral evolution.

## Questions people ask

### Is RFA-IP-24-046 still open?

No. It closed on February 16, 2024. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort)?

Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes and businesses.

### What is the deadline for Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort)?

Closed February 16, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $4.5 million each. About $26.5 million in total for one award.

### Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before?

The largest recipients over five fiscal years were Council of Medical Specia, Post-Acute and Long-Term Care Medical Association, Inc., National Health Laboratory Service. The program made 30 awards worth $58.2 million in that time.